I am a
Home I AM A Search Login

Papers of the Week

Papers: 11 Dec 2021 - 17 Dec 2021

Human Studies, Pharmacology/Drug Development


2021 Dec 13

Pain Manag

Atogepant and sumatriptan: no clinically relevant drug-drug interactions in a randomized, open-label, crossover trial.



To evaluate pharmacokinetic interactions of atogepant with sumatriptan, an open-label, randomized, crossover study was conducted. Thirty healthy adults received atogepant 60 mg, sumatriptan 100 mg, or coadministered drugs. Primary end point was geometric mean ratios (GMRs) and 90% CIs of interventions for area under the plasma concentration-time curve from time 0 to t (AUC) or infinity (AUC) and peak plasma concentration (C). Atogepant GMRs for AUC and AUC versus with sumatriptan were within 90% CI 0.80-1.25, indicating no interaction; atogepant C was reduced by 22% (GMR: 0.78; 90% CI: 0.69-0.89) with sumatriptan. Sumatriptan GMRs for AUC, AUC and C versus with atogepant were within 90% CI 0.80-1.25. Atogepant with sumatriptan had no clinically relevant pharmacokinetic interactions.